LIST OF FIGURES

Figure 1: Structures of Antileishmanial Agents. 47

Figure 2: Photomicrograph showing Leishman stained L. donovani promastigotes from a 6 day old culture in BHMARB (X200) 107

Figure 3: Photomicrograph showing Leishman stained L. donovani promastigotes from a 6 day old culture in BHMARB medium (X1000). 108

Figure 4: Growth curve of L. donovani promastigotes in BHMARB medium 109

Figure 5: A precipitin reaction profile of various antigen fractions versus human antisera. 114

Figure 6: Dry and wet weight of liver during infection. 116

Figure 7: Figure showing acid phosphatase and alkaline phosphatase contents profile from normal, infected and treated animals. 130

Figure 8: Figure showing SGPT and SGOT profile from normal infected and treated animals. 133

Figure 9: Liver section from a normal animal showing distribution of glycogen droplets in the lobules (X200). 136

Figure 10: Liver section showing depletion in the glycogen droplets in the lobules. Hepatocytes showing degenerative changes (X200). 137

Figure 11: Photomicrograph from an infected animal treated with lesser drug only showing less pigmentation of glycogen droplets (X200). 138

Figure 12: Photomicrograph from an infected animal, treated with a combined therapy of drug and TDM. Showing normal distribution of glycogen droplets (X200). 139

Figure 13: Spleen section from a normal animal showing distribution of glycogen (X200). 140

Figure 14: Spleen section from an infected animal showing depletion in the glycogen content (X200). 141

Figure 15: Spleen section from an infected animal treated with lesser drug only showing less pigmentation of glycogen (X200). 142
Figure 16: Spleen section from an infected animal treated with combined therapy of drug and TDM showing normal distribution of glycogen (X200).

Figure 17: Normal liver section showing distribution of nucleic acid throughout the lobules (X100).

Figure 18: L. donovani infected liver section showing loss of nucleic acid (X400).

Figure 19: Liver section from an infected animal treated with 10 mg drug showing less pigmentation of nucleic acid (X200).

Figure 20: Liver section from an infected animal treated with combined therapy of drug and TDM showing normal distribution of nucleic acid (X200).

Figure 21: Graph Showing The Humoral and Cellular Immune Responses in Infected and Treated Animals.

Figure 22: Liver section from a normal animal (H&E x 200).

Figure 23: Liver section from an infected control animal showing granulomatous lesions (H&E x 200).

Figure 24: Liver section from an infected animal showing Kupffer cells (H&E x 400).

Figure 25: Liver section from an infected animal as seen in higher magnification showing L.D. bodies inside Kupffer cells (H&E x 1000).

Figure 26: Photomicrograph of liver from an infected animal treated with lesser dosage of drug only showing clusters of macrophages (H&E x 200).

Figure 27: Photomicrograph of liver from an infected animal treated with a combined therapy of drug and TDM showing less inflammation around the portal vein but the cells do not contain L.D. body.

Figure 28: Photomicrograph of liver from an infected animal treated with high dosage of drug only showing less inflammation.

Figure 29: Spleen section from a normal animal (H&E x 100).

Figure 30: Spleen section from an infected animal showing white pulp invades with macrophage (H&E x 100).
Figure 31: Spleen section from an infected animal showing parasitized macrophages invading the white pulp (H&E x 400).

Figure 32: Spleen section from an infected animal as seen in higher magnification showing numerous L.D. bodies inside the macrophages (H&E x 1000).

Figure 33: Spleen section from an infected animal treated with lesser drug dosage only. Showing inflammation. Some macrophages containing L.D. are also seen (H&E x 200).

Figure 34: Spleen section from an infected animal treated with a combined therapy of drug and TDM showing normal distribution of cells (H&E x 200).